

## **Radiopharm's Pan-Cancer Targeting Monoclonal Antibody DUNP19 (RAD 502) halts tumor progression and prolongs survival in various cancer models**

- *Study by David Ulmert and colleagues demonstrated that non-invasive clinical imaging and targeted radioimmunotherapy with DUNP19 (RAD 502) can halt tumor progression and prolong survival in various cancer models.*
- *Results demonstrate that targeting LRRC15, a cellular marker expressed in certain solid tumors, with Lutetium-177-labelled DUNP19 may override immunotherapy resistance.*
- *This novel precision treatment platform holds a strong potential to preselect patients with LRRC15-expressing tumors for therapeutic dosing with <sup>177</sup>Lu-DUNP19.*

Sydney, Australia – 5 February 2024 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that a study featuring DUNP19 (RAD 502), conducted by Dr. [David Ulmert](#) and colleagues from the University of California, Los Angeles (UCLA), is now available in preprint on [BioRxiv](#).

The paper, entitled “[Development of a LRRC15-Targeted Radio-Immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance](#)”<sup>1</sup>, demonstrates for the very first time how DUNP19 can be used in various cancer models for the detection and targeting of Leucine-Rich Repeat Containing 15 (LRRC15)-expressing cancers.

LRRC15 is a cellular marker and novel therapeutic target in solid tumors (breast, head and neck, lung, pancreatic), and in cancers that arise from connective tissue (osteosarcoma, glioblastoma, melanoma)<sup>2</sup>. DUNP19 (RAD 502) is a highly specific monoclonal antibody that targets LRRC15, offering a strong potential for it to be used as a dual-purpose agent for both non-invasive imaging and the theranostic treatment of LRRC15+ aggressive cancers.

The findings in the paper propose a novel technique for imaging and treating a wide range of aggressive tumors that express LRRC15 and have limited options for targeted therapy. The results also provide early evidence for the ability of <sup>177</sup>Lu-DUNP19 to target pathways involved in immunotherapy resistance and a poor prognosis. DUNP19 (RAD 502) is currently under pre-clinical investigation at Radiopharm as a therapeutic monoclonal antibody labelled with the beta-emitting radioisotope Terbium-161.

Radiopharm's Scientific Advisory Board member and co-inventor of the DUNP19 platform Dr. David Ulmert said: "Our transcriptomic analyses of [<sup>177</sup>Lu]-DUNP19-treated tumors indicate a reduction in pro-tumorigenic mechanisms, including TGFβ-driven LRRC15+ signature associated with resistance to immunotherapy. These findings underscore the potential of radio-theranostic targeting of LRRC15 as a powerful precision medicine platform."

---

<sup>1</sup> <https://doi.org/10.1101/2024.01.30.577289>

<sup>2</sup> [Cancer Res.](#) 2022 May 3; 82(9): 1675–1681.

### **About Radiopharm Theranostics**

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of six distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world's leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumour cancers including breast, kidney and brain. Learn more at [Radiopharmtheranostics.com](https://radiopharmtheranostics.com).

**Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.**

### **For more information:**

Riccardo Canevari  
CEO & Managing Director  
P: +1 862 309 0293  
E: [rc@radiopharmtheranostics.com](mailto:rc@radiopharmtheranostics.com)

Matt Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

### **Follow Radiopharm Theranostics:**

Website – <https://radiopharmtheranostics.com/>  
Twitter – <https://twitter.com/TeamRadiopharm>  
Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>  
InvestorHub – <https://investorhub.radiopharmtheranostics.com/>

